Company: KMRK
Filing Date: 2025-03-07
Form Type: DRS/A
Source: 0001213900-25-021451
Chunk: 10

Company: K-TECH SOLUTIONS CO LTD
Filing Date: 2025-03-07
Form: DRS/A
Chunk 10
---
 ability to make dividend payments, if any, would be contingent upon our receipt of funds from our operating subsidiary, KMT. We are an “emerging growth company” and a “foreign private issuer” as defined under the federal securities laws and, as such, will be subject to reduced public company reporting requirements. See “ Prospectus Summary — Implications of Being an Emerging Growth Company and a Foreign Private Issuer ” for additional information. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. Investing in our Ordinary Shares involves a high degree of risk, including the risk of losing your entire investment. See “ Risk Factors ” beginning on page 17 of this prospectus to read about factors you should consider before buying our Ordinary Shares.

|                                           |     | Per Share |     | Total |
|:------------------------------------------|:----|:----------|:----|:------|
| IPO price                                 |     | $         |     | $     |
| Underwriting discounts and commissions(1) |     | $         |     | $     |
| Proceeds to us (before expenses)          |     | $         |     | $     |

____________ (1)We agreed to pay [*], the representative of the underwriters (the “Representative”), underwriting commissions of 7% of the gross proceeds of the offering. This does not include a non -accountableexpense allowance of 0.75% of the gross proceeds of this offering payable to the Representative. Refer to “Underwriting” for additional information regarding underwriting compensation. This offering is being conducted on a firm commitment basis. The underwriters are obligated to take and pay for all of the Shares if any such shares are taken. In addition, we have agreed to grant the underwriters an option for a period of 45 days after the closing of this offering to purchase up to 15% of the total number of our Ordinary Shares to be offered by us pursuant to this offering (the “Overallotment Option”), solely for the purpose of covering overallotments, at the IPO price less the underwriting discount. If the underwriters exercise the Overallotment Option in full, the total underwriting discounts payable will be $[*] and the total proceeds to us, after underwriting discounts but before offering expenses, will be approximately $[*]. If we complete this offering, net proceeds will be delivered to our Company on